Vanhaver Christophe, van der Bruggen Pierre, Bruger Annika M
De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 74, 1200 Brussels, Belgium.
WELBIO, Avenue Hippocrate 74, 1200 Brussels, Belgium.
J Clin Med. 2021 Jun 28;10(13):2872. doi: 10.3390/jcm10132872.
Myeloid-derived suppressor cells (MDSCs) expand during pathological conditions in both humans and mice and their presence is linked to poor clinical outcomes for cancer patients. Studying MDSC immunosuppression is restricted by MDSCs' rarity, short lifespan, heterogeneity, poor viability after freezing and the lack of MDSC-specific markers. In this review, we will compare identification and isolation strategies for human and murine MDSCs. We will also assess what direct and indirect immunosuppressive mechanisms have been attributed to MDSCs. While some immunosuppressive mechanisms are well-documented in mice, e.g., generation of ROS, direct evidence is still lacking in humans. In future, bulk or single-cell genomics could elucidate which phenotypic and functional phenotypes MDSCs adopt in particular microenvironments and help to identify potential targets for therapy.
髓源性抑制细胞(MDSCs)在人类和小鼠的病理状态下都会扩增,它们的存在与癌症患者不良的临床预后相关。由于MDSCs数量稀少、寿命短、异质性高、冷冻后活力差以及缺乏MDSC特异性标志物,对其免疫抑制作用的研究受到限制。在这篇综述中,我们将比较人类和小鼠MDSCs的鉴定和分离策略。我们还将评估哪些直接和间接的免疫抑制机制被归因于MDSCs。虽然一些免疫抑制机制在小鼠中已有充分记录,例如活性氧的产生,但在人类中仍缺乏直接证据。未来,批量或单细胞基因组学可以阐明MDSCs在特定微环境中呈现的表型和功能表型,并有助于确定潜在的治疗靶点。